IME:CSE; IMEXF:OTCQB

Imagin Medical Inc.

Imagin Medical is a surgical imaging company developing advanced optic and light sensor technology to dramatically improve physicians' ability to visualize cancer during minimally invasive surgery.
IME:CSE IMEXF:OTCQB
Technical analyst Clive Maund charts the stock of this company that has developed a device that uses a special light that visualizes cancer during minimally invasive surgery.
read more >
The surgical imaging firm continues to advance its first medical device toward commercialization.
read more >

Experts Following This Company

Clive Maund – CliveMaund.com

The information provided above is from analysts, newsletters, the company and other contributors.

Imagin Medical Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Bringing new standard of care to bladder cancer through surgical imaging
 
Early stage opportunity - $4B market opportunity - most expensive cancer to treat due to recurrence
 
Poised for strategic growth with strong management
catalyst Calendar
Q2
2019
Functional Unit
Q3
2019
Verified Unit
Q4
2019
FDA Approval